Evaluation of continuous infusion low‐dose 5‐azacytidine in the treatment of myelodysplastic syndromes

No abstract is available for this paper.

• Publication year

  1991

• Venue

  American journal of hematology/oncology

• Publication date

  1991-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.2830370207PMID 1712548
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.

  1990cited by this paper
• Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.

  1990cited by this paper
• The myelodysplastic syndromes: biology and implications for management.

  1990cited by this paper
• The myelodysplastic syndromes: current approaches to therapy.

  1990cited by this paper
• Partially matched bone marrow transplantation in patients with myelodysplastic syndromes.

  1988cited by this paper
• High-performance liquid chromatographic determination of 5-azacytidine in plasma.

  1987cited by this paper
• High-performance liquid chromatographic determination of

  1987cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper
• Human preleukemia.

  1980cited by this paper
• DNA methylation and gene function.

  1980cited by this paper
• Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine.

  1979cited by this paper

• Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

  2019cites this paper
• Treatment with Hypomethylating Agents (HMA)

  2018cites this paper
• Azacitidine Use for Myeloid Neoplasms

  2018cites this paper
• Targeting Histone Methylation in Cancer.

  2017cites this paper
• AML multi-gene panel testing: A review and comparison of two gene panels.

  2016cites this paper
• Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.

  2016cites this paper
• RETRACTED ARTICLE: 5-Azacitidine for treating acute myelogenous leukemia

  2015cites this paper
• Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

  2015cites this paper
• Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies

  2014cites this paper
• Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy

  2014cites this paper
• Epigenetic therapies in MDS and AML.

  2013cites this paper
• Azacitidine in the management of patients with myelodysplastic syndromes

  2012cites this paper
• Mutations in DNA Methyltransferase (DNMT3A) Observed in Acute Myeloid Leukemia Patients Disrupt Processive Methylation

  2012cites this paper
• Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes

  2012cites this paper
• Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes

  2011cites this paper
• The History of the Myelodysplastic Syndromes

  2011cites this paper
• syndrome and acute myeloid leukemia Allogeneic transplantation for therapy-related myelodysplastic

  2011influential citation
• Modulation of Pharmacologic Effects of 5-Azacytidine by Ribonucleotide Reductase Antisense GTI-2040

  2011cites this paper
• 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

  2010cites this paper
• [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].

  2010cites this paper
• Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

  2010influential citation
• Azacitidine for the treatment of myelodysplastic syndrome

  2009cites this paper
• Update on the therapy for myelodysplastic syndrome

  2009cites this paper
• Epigenetics in Biology and Medicine

  2008cites this paper
• Pharmacokinetic-Pharmacodynamic Studies Of 5-Azacytidine In Combination With Gti-2040

  2008influential citation
• DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.

  2008cites this paper
• The role of azacitidine in the treatment of myelodysplastic syndromes

  2007cites this paper
• The use of hypomethylating agents in the treatment of hematologic malignancies

  2007cites this paper
• Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.

  2007cites this paper
• Epigenetische Inaktivierung von Genexpression

  2006cites this paper
• DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML.

  2006cites this paper
• FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

  2005cites this paper
• Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.

  2005cites this paper
• Biologically targeted therapies for myelodysplastic syndromes

  2005cites this paper
• Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.

  2005cites this paper
• Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

  2005cites this paper
• Advances in myelodysplastic syndrome: nursing implications of azacitidine.

  2005cites this paper
• DNA methyltransferase inhibitors in myelodysplastic syndrome.

  2004cites this paper
• DNA Demethylating Agents: Clinical Uses

  2004cites this paper
• Recent progress in the treatment of myelodysplastic syndrome in adult patients

  2003cites this paper
• Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.

  2003cites this paper
• Induction of Epstein-Barr Virus Kinases To Sensitize Tumor Cells to Nucleoside Analogues

  2001cites this paper
• Long-term silencing of retroviral vectors is resistant to reversal by trichostatin A and 5-azacytidine

  2000cites this paper
• DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.

  2000cites this paper
• Novel therapeutic agents for the treatment of myelodysplastic syndromes.

  2000cites this paper
• Treatment of adult myelodysplastic syndromes.

  1999cites this paper
• Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes.

  1998cites this paper
• A patient-oriented approach to treatment of myelodysplastic syndromes.

  1998cites this paper
• Recent Advances in Myelodysplastic Syndromes

  1998cites this paper
• Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia

  1997cites this paper
• The Myelodysplastic Syndromes.

  1997cites this paper
• Myelodysplastic syndromes.

  1996cites this paper
• The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes.

  1995cites this paper
• Biology and treatment of myelodysplastic syndromes — developments in the past decade

  1993cites this paper
• Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia.

  1993cites this paper
• 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.

  1993cites this paper
• Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes.

  1993cites this paper
• Treatment with Azacitidine of Patients with End-Stage β-Thalassemia

  1993cites this paper
• 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.

  1993cites this paper
• Myelodysplastic syndromes: Pathogenesis, diagnosis and treatment

  1992cites this paper